Translational medical research is a two-way process. On one hand it concerns the process whereby the findings of basic research are converted into new approaches for the diagnosis and therapy of disease. On the other hand it involves the conversion of clinical observations into basic research questions that can be addressed in the laboratory. Commercial research and development also plays a key role in the translational process that leads from research findings to implementation in the healthcare system.

Launched in 2009, the Master of Science in Translational Medical Research (MSc TMR) programme systemically provides students who already have a medical or bioscience background with the knowledge and skills necessary to participate in the frontier of translational medical research. It is a consecutive course that lasts one year, and requires that students have obtained 240 ECTS during their bachelor training.

More information about the MScTMR programme can be found on the pages of the University of Heidelberg.

The MSc TMR programme is an integral component of the Erasmus+ International Master in Innovative Medicine IMIM an international masters programme. Established in 2016, IMIM is supported in part through EU financing, and fosters the education of future translational biomedical researchers. IMIM is a joint venture between three European universities, which together provide the four constituent masters programmes that form the framework of the IMIM programme:

• MSc Medical and Pharmaceutical Drug Innovation at the University of Groningen
• MSc Translational Medical Research at Heidelberg University
• MMS Molecular Medicine and the MMS Medical Research at Uppsala University

Competitive Erasmus+ scholarships are offered for this two-year course. Students need to have acquired 180 ECTS during their bachelor training to study the course. For more information, please see the IMIM website.